Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patent settlements
Pharma
China biotech deals, Takeda, LaNova—Fierce Pharma Asia
Biotech deals originating out of China are surging. Takeda touts a pair of OX2R phase 3 wins. Merck's PD-1xVEGF partner is being acquired. And more.
Angus Liu
Jul 18, 2025 9:04am
Teva agrees with Axsome to keep generic off market until 2038
Feb 10, 2025 11:28am
Catalyst's Teva settlement postpones arrival of Firdapse generic
Jan 9, 2025 10:08am
BeiGene defends Brukinsa from MSN's generic threat until 2037
Nov 19, 2024 3:55pm
Alkermes grants Teva license to launch generic Vivitrol in 2027
Aug 31, 2023 10:05am
BMS, AZ settle cancer immunotherapy patent suits for $510M
Aug 1, 2023 10:09am
